'We are delighted': Belfast biotech firm secures £45,000 project with global pharmaceutical company
Fusion Antibodies secures a £45,000-plus antibody engineering project, using its proprietary RAMP technology for an established pharmaceutical client.
A Belfast-based biotechnology firm has secured a new affinity engineering project worth more than £45,000 for a European-listed global pharmaceutical company.
Fusion Antibodies specialises in pre-clinical antibody discovery, engineering and supply for therapeutic drug and diagnostic applications. It secured the project using its proprietary Rational Affinity Maturation Programme (RAMP) technology.
The project involves affinity engineering of the client’s lead antibody and has been awarded under an existing master services agreement.
Fusion has previously undertaken similar work for the client, with the latest award representing renewed engagement with an established pharmaceutical partner.
The RAMP project is expected to generate revenues in excess of £45,000, with the work due to be completed within the company’s current financial year.
The award represents further business from an established pharmaceutical client and demonstrates Fusion’s ability to build on existing relationships through its specialist antibody engineering capabilities.
It also supports the company’s strategy of developing deeper commercial relationships with major pharmaceutical companies, strengthening the quality and resilience of its revenue base and creating opportunities for recurring business.
The technically complex project further demonstrates the relevance of Fusion’s specialist capabilities as it seeks to commercialise technologies including RAMP, OptiMAL and microfluidic cell line development.
Adrian Kinkaid, chief executive of Fusion Antibodies, said: “We are delighted to have secured this new RAMP project with a returning global pharmaceutical client. It is particularly encouraging to re-engage with an established customer for whom we have previously undertaken similar work, demonstrating the continued relevance of our specialist antibody engineering capabilities.
“The award provides a further opportunity to apply our proprietary RAMP technology to the development of the Client’s lead antibody. Our focus remains on delivering high-quality antibody engineering services and building deeper relationships with major pharmaceutical companies, creating opportunities for further collaboration.”